Allogene Therapeutics (ALLO) Change in Account Payables: 2019-2025
Historic Change in Account Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$1.1 million.
- Allogene Therapeutics' Change in Account Payables rose 85.17% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 114.06%. This contributed to the annual value of -$503,000 for FY2024, which is 93.30% up from last year.
- Latest data reveals that Allogene Therapeutics reported Change in Account Payables of -$1.1 million as of Q3 2025, which was down 154.03% from -$422,000 recorded in Q2 2025.
- Allogene Therapeutics' Change in Account Payables' 5-year high stood at $6.8 million during Q2 2024, with a 5-year trough of -$7.2 million in Q3 2024.
- Over the past 3 years, Allogene Therapeutics' median Change in Account Payables value was -$336,000 (recorded in 2025), while the average stood at -$894,091.
- The largest annual percentage gain for Allogene Therapeutics' Change in Account Payables in the last 5 years was 497.70% (2021), contrasted with its biggest fall of 666.36% (2021).
- Allogene Therapeutics' Change in Account Payables (Quarterly) stood at -$2.0 million in 2021, then soared by 243.74% to $2.9 million in 2022, then tumbled by 110.28% to -$302,000 in 2023, then spiked by 111.26% to $34,000 in 2024, then skyrocketed by 85.17% to -$1.1 million in 2025.
- Its Change in Account Payables stands at -$1.1 million for Q3 2025, versus -$422,000 for Q2 2025 and -$336,000 for Q1 2025.